- Previous Close
45.28 - Open
46.98 - Bid --
- Ask --
- Day's Range
44.59 - 47.54 - 52 Week Range
32.85 - 74.80 - Volume
58,276 - Avg. Volume
32,672 - Market Cap (intraday)
1.345B - Beta (5Y Monthly) 0.63
- PE Ratio (TTM)
22.30 - EPS (TTM)
2.11 - Earnings Date May 28, 2025 - Jun 2, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Aarey Drugs & Pharmaceuticals Limited manufactures and sells active pharmaceutical ingredients, intermediates, and specialty chemicals for various industrial applications in India. The company provides mono methyl and die methyl urea, ortho para nitro anisole, 2 bromomethyl 1, and 3 dioxalane and uracile, as well as active pharma ingredients, such as metformin HCL, mefenamic acid, and doxophylline. It also offers chemicals and solvents, including aromatic chemicals, chemical acids, chlor alkalies, glycols and glycol ethers, fiber intermediates, acetates and esters, and chlorinated solvents, as well as industrial alchols, ketones, amines, oleochemicals, intermediates, olefines, phosphates, fertilizers, monomers, and chemicals. In addition, the company trades in industrial solvents and chemicals.The company's pharmaceutical products are used by pharmaceutical formulation manufacturers and pharmaceutical merchant exporters. Aarey Drugs & Pharmaceuticals Limited was incorporated in 1990 and is headquartered in Mumbai, India.
www.aareydrugs.com--
Full Time Employees
March 31
Fiscal Year Ends
Sector
Recent News: AAREYDRUGS.NS
View MorePerformance Overview: AAREYDRUGS.NS
Trailing total returns as of 4/8/2025, which may include dividends or other distributions. Benchmark is S&P BSE SENSEX (^BSESN) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: AAREYDRUGS.NS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: AAREYDRUGS.NS
View MoreValuation Measures
Market Cap
1.29B
Enterprise Value
1.67B
Trailing P/E
21.43
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.22
Price/Book (mrq)
0.95
Enterprise Value/Revenue
0.29
Enterprise Value/EBITDA
12.80
Financial Highlights
Profitability and Income Statement
Profit Margin
0.99%
Return on Assets (ttm)
--
Return on Equity (ttm)
--
Revenue (ttm)
5.76B
Net Income Avi to Common (ttm)
57.06M
Diluted EPS (ttm)
2.11
Balance Sheet and Cash Flow
Total Cash (mrq)
14.9M
Total Debt/Equity (mrq)
28.51%
Levered Free Cash Flow (ttm)
--